# 百時美施貴寶多發性骨髓瘤藥物在晚期研究中提升存活率50%。

*biotech · news · 2026-05-29 · Seeking Alpha*

## Key points

- 百時美施貴寶的mezigdomide在晚期骨髓瘤試驗中將無癌生存期提升超過50%。
- Mezigdomide作為多發性骨髓瘤的組合療法之一進行測試。
- 此結果來自晚期或第三期臨床試驗。
- Mezigdomide是一款專門為多發性骨髓瘤治療開發的抗腫瘤候選藥物。

Bristol Myers multiple myeloma drug improves survival by 50% in late-stage study May 29, 2026, 9:09 AM ETBristol-Myers Squibb Company (BMY) StockKDBy : Dulan Lokuwithana, SA News Editor Comments (2) Bristol Myers Squibb (BMY) announced on Friday that its antitumor candidate mezigdomide, as part of a combination regimen, improved cancer-free survival by more than 50% in a late-stage trial for multiple myeloma, a type of blood cancer. Citing data from Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters

**Companies:** Bristol Myers Squibb

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4598379-bristol-myers-posts-phase-3-win-multiple-myeloma-drug)

---

Canonical: https://newsio.io/zh-TW/n/96dfaf68-11b4-4c4d-946a-5096b7603b8f/50
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works